Meloxicam Tablets, 7.5 mg and 15 mg

/Meloxicam Tablets, 7.5 mg and 15 mg
Meloxicam Tablets, 7.5 mg and 15 mg2018-09-06T09:12:40+00:00

Prescription Drug Name:

Meloxicam Tablets, 7.5 mg and 15 mg






id: 6e5fb31c-97f6-45c2-9e7e-aa7737e45e98
FDA Article Code: 34089-3

Meloxicam, an oxicam derivative, is a member of the enolic acid group of nonsteroidal anti-inflammatory drugs (NSAIDs). Each pastel yellow Meloxicam tablet USP contains 7.5 mg or 15 mg meloxicam for oral administration. Meloxicam is chemically designated as 4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide. The molecular weight is 351.4. Its empirical formula is C14H13N3O4S2 and it has the following structural formula. Meloxicam is a pastel yellow solid, practically insoluble in water, with higher solubility observed in strong acids and bases. It is very slightly soluble in methanol. Meloxicam has an apparent partition coefficient (log P)app = 0.1 in n-octanol/buffer pH 7.4. Meloxicam has pKa values of 1.1 and 4.2. Meloxicam is available as a tablet for oral administration containing 7.5 mg or 15 mg meloxicam. The inactive ingredients in Meloxicam tablets USP include colloidal silicon dioxide, crospovidone, lactose monohydrate, magnesium stearate, microcrystalline cellulose, povidone and sodium citrate dihydrate.


id: 5c1b8988-fa43-4beb-bfb3-bdd9cf545e9f
FDA Article Code: 34067-9

Carefully consider the potential benefits and risks of meloxicam and other treatment options before deciding to use meloxicam. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Meloxicam is indicated for relief of the signs and symptoms of osteoarthritis and rheumatoid arthritis.


id: abd91ff4-6809-4b9b-90a5-e62b363f5aaf
FDA Article Code: 34070-3

Meloxicam is contraindicated in patients with known hypersensitivity to meloxicam. Meloxicam should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. Severe, rarely fatal, anaphylactic-like reactions to NSAIDs have been reported in such patients (see WARNINGS , Anaphylactoid Reactions , and PRECAUTIONS , Pre-existing Asthma ). Meloxicam is contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery (see WARNINGS ).


id: 3c561f78-2075-4830-b00d-90252c2606af
FDA Article Code: 34088-5

There is limited experience with meloxicam overdose. Four cases have taken 6 to 11 times the highest recommended dose; all recovered. Cholestyramine is known to accelerate the clearance of meloxicam. Symptoms following acute NSAID overdose are usually limited to lethargy, drowsiness, nausea, vomiting, and epigastric pain, which are generally reversible with supportive care. Gastrointestinal bleeding can occur. Severe poisoning may result in hypertension, acute renal failure, hepatic dysfunction, respiratory depression, coma, convulsions, cardiovascular collapse, and cardiac arrest. Anaphylactoid reactions have been reported with therapeutic ingestion of NSAIDs, and may occur following an overdose. Patients should be managed with symptomatic and supportive care following an NSAID overdose. In cases of acute overdose, gastric lavage followed by activated charcoal is recommended. Gastric lavage performed more than one hour after overdose has little benefit in the treatment of overdose. Administration of activated charcoal is recommended for patients who present 1-2 hours after overdose. For substantial overdose or severely symptomatic patients, activated charcoal may be administered repeatedly. Accelerated removal of meloxicam by 4 gm oral doses of cholestyramine given three times a day was demonstrated in a clinical trial. Administration of cholestyramine may be useful following an overdose. Forced diuresis, alkalinization of urine, hemodialysis, or hemoperfusion may not be useful due to high protein binding.


id: ff1c743d-cf2e-4bff-9a1f-bbd1bbf9cbdc
FDA Article Code: 34069-5

Meloxicam Tablets USP are available as light yellow, round, flat, uncoated tablets containing meloxicam 7.5 mg or as light yellow, oblong, biconvex, uncoated tablets containing meloxicam 15 mg. The 7.5 mg tablet is impressed with letter U and L on one side and tablet code 7.5 on the other side. The 15 mg tablet is impressed with letter U and L on one side and tablet code 15 on the other side. Meloxicam Tablets USP 7.5 mg are available as follows: NDC 21695-076-14; Bottles of 14 NDC 21695-076-15; Bottles of 15 NDC 21695-076-30; Bottles of 30 NDC 21695-076-60; Bottles of 60 NDC 21695-076-90; Bottles of 90 Meloxicam Tablets USP 15 mg are available as follows: NDC 21695-077-14; Bottles of 14 NDC 21695-077-15; Bottles of 15 NDC 21695-077-30; Bottles of 30 NDC 21695-077-60; Bottles of 60


id: 2d945ab2-5d1f-4dff-9d58-977436f99516
FDA Article Code: 44425-7

Store at Controlled Room Temperature 20°-25°C (68°-77°F) [See USP] Please address medical inquiries to Keep meloxicam tablets in a dry place Dispense tablets in a tight container. Keep this and all medications out of the reach of children.